SCHEMBL7726010

SCHEMBL7726010

CCCCn1ccc(-c2cc(OCc3ccccc3)ccc2OC)c(C(=O)O)c1=O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 1/20 0.41
MAPT P10636 2/20 0.40
KDM4E B2RXH2 2/20 0.40
FFAR1 O14842 2/20 0.40
SRD5A2 P31213 1/20 0.40
GSK3B P49841 1/20 0.39
MAPK14 Q16539 1/20 0.39
TP53 P04637 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
STK10 O94804 1/20 0.39
SLK Q9H2G2 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MTNR1A P48039 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7735544 0.91 EDNRA (0.41) TOP1FFAR1SRD5A2MAPK14
SCHEMBL7736093 0.88 KDM4E (0.47) MAPTKDM4EMEN1KMT2ANPC1
SCHEMBL7726016 0.86 EDNRA (0.42) TOP1SRD5A2MAPK14
SCHEMBL7735835 0.85 MTNR1A (0.43) MAPTKDM4EMAPK14TP53NPC1
SCHEMBL7737859 0.84 MEN1 (0.45) KDM4EMEN1KMT2AHPGDHSD17B10
SCHEMBL7736063 0.81 ALDH1A1 (0.42) KDM4EMEN1KMT2AHPGDHSD17B10
SCHEMBL7735552 0.81 BRD9 (0.40) MAPTKDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL7725867 0.80 LPAR1 (0.42)
SCHEMBL7736088 0.79 PTGER4 (0.44) FFAR1MEN1KMT2A
SCHEMBL7736090 0.79 TLR4 (0.43) MAPTMAPK14HSD17B10MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452008-B2 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-17 US disclosed
US-20010051732-A1 Pyridone derivatives and process for preparing the same SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2001-12-13 US disclosed
US-6300500-B1 Preparation of pyridone derivatives using phthalimido containing starting material SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-10-09 US disclosed
EP-1086948-A1 PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051732-A1 Pyridone derivatives and process for preparing the same HK1, HPD, ALK TOP1 1303/4885MAPT 2933/4885KDM4E 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.